Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced the publication of a manuscript in Gynecologic Oncology, found here, validating the performance of its personalized molecular residual disease (MRD) test, Signatera, in epithelial ovarian cancer (EOC). This study adds to the growing library of over 30 published clinical studies incorporating Signatera technology.
The blinded, multi-site study analyzed 163 plasma samples from 69 patients with Stage I-IV disease across a range of histologies, including high-grade serous (54%), endometrioid (13%), clear cell (13%) and other (20%). Test performance was evaluated at multiple time points: pre-surgery, post-surgery prior to adjuvant treatment, and longitudinally every 3 months for up to 40 months after the completion of definitive therapy. With longitudinal testing, recurrence was detected with 100% sensitivity, 100% specificity, and an average lead time of 10 months ahead of imaging compared to 1 month for CA-125.
Read more here
Don’t miss the next article from HealthFirst 100.
Join our mailing list to receive the latest posts from our blog directly in your inbox.